64993-07-3

Usage

Uses

Used in Pharmaceutical Industry:
6-NITRO-1,3-BENZODIOXOL-5-AMINE is used as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs, particularly those targeting specific biological pathways or diseases.
Used in Agrochemical Industry:
6-NITRO-1,3-BENZODIOXOL-5-AMINE is also utilized in the production of agrochemicals, where it serves as a precursor for the synthesis of active ingredients in pesticides and other agricultural chemicals. Its role in this industry is crucial for the development of effective and targeted pest control solutions.
Due to its potential mutagenicity and environmental hazards, it is essential to implement proper handling and disposal protocols when working with 6-NITRO-1,3-BENZODIOXOL-5-AMINE in both the pharmaceutical and agrochemical industries. This ensures the safety of workers, the environment, and the public.

InChI:InChI=1/C7H6N2O4/c8-4-1-6-7(13-3-12-6)2-5(4)9(10)11/h1-2H,3,8H2

Upstream product

• 7748-59-6 5,6-dinitro-benzo[1,3]dioxole 
• 64-17-5 ethanol 
• 7748-57-4 5-chloro-6-nitro-benzo[1,3]dioxole 
• 7664-41-7 ammonia 
• 81864-14-4 N-(6-Nitrobenzo[d][1,3]dioxol-5-yl)acetamide 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 13067-19-1 3,4-methylenedioxyacetanilide 

Downstream Products

• 7107-10-0 4-hydroxy-5-nitro-1,2,methylenedioxybenzene 
• 93415-78-2 N-(2'-Carbomethoxy-6'-nitrophenyl)-5-amino-6-nitro-1,3-benzdioxol 
• 892123-42-1 C₁₆H₁₃N₃O₉ 
• 7106-74-3 5-Iodo-6-nitrobenzo[d][1,3]dioxole 
• 81864-15-5 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride 

Relevant academic research and scientific papers

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

A Novel Difluoroacetic Acid Derivatives Compound, and Composition Comprising the Same

The present invention relates to a novel difluoroacetic acid derivative compound and a composition for various uses containing the same, wherein the difluoroacetic acid derivative compound can not only act as an agonist activating one among PPARandalpha;, andbeta; or andgamma;, but also can exhibit double efficacy or triple efficacy. Therefore, the difluoroacetic acid derivative compound can more effectively prevent, alleviate or treat metabolic diseases in which PPARs involves, and further exhibits whitening and wrinkle alleviation activity, and anti-inflammatory and antioxidant effects, thereby being able to be usefully utilized as various compositions.COPYRIGHT KIPO 2020

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

A series of novel tricyclic triazine-di-N-oxides (TTOs) related to tirapazamine have been designed and prepared. A wide range of structural arrangements with cycloalkyl, oxygen-, and nitrogen-containing saturated rings fused to the triazine core, coupled with various side chains linked to either hemisphere, resulted in TTO analogues that displayed hypoxia-selective cytotoxicity in vitro. Optimal rates of hypoxic metabolism and tissue diffusion coefficients were achieved with fused cycloalkyl rings in combination with both the 3-aminoalkyl or 3-alkyl substituents linked to weakly basic soluble amines. The selection was further refined using pharmacokinetic/pharmacodynamic model predictions of the in vivo hypoxic potency (AUCreq) and selectivity (HCD) with 12 TTO analogues predicted to be active in vivo, subject to the achievement of adequate plasma pharmacokinetics.

FUSED AMINO PYRIDINE AS HSP90 INHIBITORS

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

TOPOISOMERASE INHIBITORS AND PRODRUGS

Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.

Nitroaminophenols and their use in dyeing keratinous fibres.

New nitroaminophenols, the process for preparation thereof and their use in dyeing keratinous fibres, and new intermediate nitroaminobenzenes and their use in dyeing keratinous fibres. The invention relates to a nitroaminophenol of formula: STR1 in which

Imidazole derivatives

Tricyclic imidazole derivatives of the formula STR1 wherein R1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R2 is hydrogen or lower alkyl, R3 and R4, independently, are hydrogen or lower alkyl, A is a group of the formula STR2 m is the integer 2 or 3, R5, R6, R7 and R8, independently, are hydrogen or lower alkyl, and R9 is hydrogen and R10 is hydrogen or lower alkyl or R9 and R10 taken together are oxo, provided that at least one of R3 and R4 is lower alkyl when A is a group of the formula and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.